Daisy Cortes
Pediatric Hematology-Oncology · Las Vegas, NVNPI 1215234356
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $242,273 of the $384,537 with a category attached, or 63.0%. 30 manufacturers reported payments, led by Novo Nordisk at 54.3% of the total. 2025 is the largest year on record at $150,260, 9.3 times the $16,111 reported in 2019.
Across 499 payments — averaging $770.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$209K
- Sanofi$87K
- Genentech USA, Inc.$19K
- Bayer$17K
- CSL Behring$15K
- Octapharma USA, Inc.$12K
- plus $25K from 24 others
Across 2 payments — averaging $1268.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
What the payments were for
- Consulting fees$92,62424%
- Speaking & faculty fees$242,27363%
- Travel & lodging$32,6338%
- Food & beverage$16,7144%
- Education$2940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 127 | $208,840 |
| Sanofi | 61 | $86,574 |
| Genentech USA, Inc. | 32 | $18,972 |
| Bayer | 31 | $16,830 |
| CSL Behring | 18 | $15,443 |
| Octapharma USA, Inc. | 68 | $12,408 |
| Pfizer | 21 | $6,820 |
| Shire North American Group Inc | 17 | $5,765 |
| Genentech, Inc. | 22 | $3,568 |
| Bio Products Laboratory USA, Inc. | 10 | $3,201 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $2,451 |
| Kedrion Biopharma, Inc. | 9 | $589 |
| Spark Therapeutics, Inc. | 7 | $453 |
| Grifols Shared Services North America, Inc. | 7 | $356 |
| Grifols USA, LLC | 10 | $343 |
| Agios Pharmaceuticals, Inc. | 5 | $275 |
| Bioverativ Therapeutics Inc. | 3 | $263 |
| Global Blood Therapeutics, Inc. | 11 | $255 |
| Incyte Corporation | 2 | $224 |
| Chiesi USA, Inc. | 9 | $193 |
| Medexus Pharma, Inc. | 4 | $149 |
| HEMA Biologics, LLC | 6 | $142 |
| Biomarin Pharmaceutical Inc. | 3 | $101 |
| Astellas Pharma US Inc | 1 | $99 |
| Novartis | 1 | $90 |
| RARE Disease Therapeutics, Inc. | 2 | $46 |
| Aptevo Therapeutics Inc | 2 | $42 |
| Kedrion Biopharma Inc. | 1 | $19 |
| Duchesnay USA Incorporated | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTUVIIIO$42,707
- QFITLIA$38,415
- REBINYN$33,842
- Esperoct$30,729
- NovoSeven$21,722
- HEMLIBRA$21,043
- Idelvion$13,483
- NUWIQ$7,651
- HEMGENIX$7,582
- HYMPAVZI$6,400
- Alhemo$4,913
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$3,625
- Jivi$2,707
- ELOCTATE$622
- ALPROLIX$621
- Coagadex$557
- Albuked$470
- KOATE$470
- GAMMAKED$470
- KEDRAB$470
How this compares
Too few pediatric hematology-oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.
Other pediatric hematology-oncology in Las Vegas
- Jenny Gober McDanielLas Vegas$43K
- Aimee FoordLas Vegas$41K
- Nik Nik Abdul RashidLas Vegas$32K
- Joseph LaskyLas Vegas$16K
- Jerry ReevesLas Vegas$12K
- Waseem AlhushkiLas Vegas$3K
- Alan IkedaLas Vegas$1K
- Michael GrahamLas Vegas$1K
- Sumit GuptaLas Vegas$1K
- Raul Montiel-EsparzaLas Vegas$794
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.